CAMBRIDGE, MA., – June 14, 2023 – HiFiBiO Therapeutics founder, Chairperson and CEO Liang Schweizer speaks with Rahul Chaturvedi on the Biotech2050 Podcast about her journey from scientist to first-time CEO and how HiFiBiO is improving the success rate of immunotherapies by leveraging unprecedented single-cell level insights into patient heterogeneity.
HiFiBiO aims at changing the conventional way in which novel immunotherapies are developed, targeting the biology of a disease rather than disease histotypes. To achieve this, HiFiBiO employs its unique Drug Intelligence Science (DIS®) platform, which combines a proprietary microfluidic single-cell platform with advanced AI/ML-based data analytics, to gain insights into human disease biology at the single-cell level allowing for precise treatment of patients based on their underlying disease mechanisms. HiFiBiO’s approach distinguishes itself from others by applying single-cell science at every stage of drug development, including discovery of novel targets, therapeutic antibodies, and predictive biomarkers, enabling rapid advancement of new therapeutics into the clinic. Since 2017, the company’s global team of scientists has utilized DIS® to build a deep discovery pipeline targeting key mechanisms of immune modulation, with three novel IO programs currently advancing through Phase I clinical trials.
Read Liang’s recently published publication paper on the advantages of going global as a biotech here.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical stage biotech company advancing a robust pipeline targeting both the innate and adaptive immunity to treat cancer and autoimmune diseases. Its proprietary and versatile DIS® single-cell platform enables the rapid discovery of novel antibody therapeutics with predictive biomarkers through our internal development programs and strategic collaborations. Our passionate team across three continents embraces a fast-paced and engaging work environment to bring transformative medicines to patients. www.hifibio.com
HiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS® are trademarks of HiFiBiO and its affiliates.